Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Haemothorax, Pleuropericarditis
Clinical narrative: Hemorrhagic pleuropericarditis; Hemorrhagic pleuropericarditis; This literature-non-study case was reported in a literature article and describes the occurrence of HAEMOTHORAX (Hemorrhagic pleuropericarditis) and PLEUROPERICARDITIS (Hemorrhagic pleuropericarditis) in a 64-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.   No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced HAEMOTHORAX (Hemorrhagic pleuropericarditis) (seriousness criterion medically significant) and PLEUROPERICARDITIS (Hemorrhagic pleuropericarditis) (seriousness criterion medically significant). The patient was treated with COLCHICINE at an unspecified dose and frequency. At the time of the report, HAEMOTHORAX (Hemorrhagic pleuropericarditis) and PLEUROPERICARDITIS (Hemorrhagic pleuropericarditis) had resolved. Related      For mRNA-1273 (Spikevax) (Unknown), the reporter considered HAEMOTHORAX (Hemorrhagic pleuropericarditis) and PLEUROPERICARDITIS (Hemorrhagic pleuropericarditis) to be related.    No Concomitant medications were reported. Patient experienced chest pain and shortness of breath one week after receiving the Moderna. Patient was found to have a large, left-sided pleural effusion and a small pericardial effusion. The patient underwent thoracentesis and video-assisted thoracoscopic procedure with chest tube placement, which drained bloody pleural and pericardial fluid. Subsequent imaging revealed the resolution of pericardial and pleural effusions, along with the resolution of symptoms. Company comment This literature-non-study case reported by a physician concerns a 64-year-old male patient, with no medical history reported, who experienced serious, medically significant, expected AESI of Pleuropericarditis and the serious, medically significant, unexpected events of pericardial haemorrhage and Haemothorax, one week after receiving the second dose of mRNA-1273 vaccine. Symptoms included chest pain and shortness of breath. The case reported hemorrhagic pleuropericarditis as event. Patient was found to have a large, left-sided pleural effusion and a small pericardial effusion. He underwent thoracentesis and video-assisted thoracoscopic procedure with chest tube placement, which drained bloody pleural and pericardial fluid. Subsequent imaging revealed the resolution of pericardial and pleural effusions, along with the resolution of symptoms. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This literature-non-study case reported by a physician concerns a 64-year-old male patient, with no medical history reported, who experienced serious, medically significant, expected AESI of Pleuropericarditis and the serious, medically significant, unexpected events of pericardial haemorrhage and Haemothorax, one week after receiving the second dose of mRNA-1273 vaccine. Symptoms included chest pain and shortness of breath. The case reported hemorrhagic pleuropericarditis as event. Patient was found to have a large, left-sided pleural effusion and a small pericardial effusion. He underwent thoracentesis and video-assisted thoracoscopic procedure with chest tube placement, which drained bloody pleural and pericardial fluid. Subsequent imaging revealed the resolution of pericardial and pleural effusions, along with the resolution of symptoms. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.